University of Wollongong - Research Network for Metals in Medicine
Download
Report
Transcript University of Wollongong - Research Network for Metals in Medicine
Metals in Medicine Research
University of Wollongong
Institute for Biomolecular
Science (IBS)
Project areas include:
14 Academic Staff
Dept. of Chemistry
Dept. of Biology
9 Postdocs
30 PhD Students
B. Med Chem
B. Biotech
Drug design and
development
Biomolecular structure
determination
Cellular and molecular
biology
Food and natural product
chemistry
Mechanism of cataract
formation
Interactions of Gold Drugs with
Proteins
-
O2C CH2
H
C
H
Au S
CO2-
CH2
Au S
(n)
Myochrysin
CH2OAc
O
OAc
OAc
OAc
Auranofin
HC
OH
CH2
SO3Na
(n)
Allochyrsine
S
Au PEt3
How does Chrysotherapy Work?
Many possible mechanisms of action:
Anti-inflammatory
Inhibition of lysosomal enzymes
Immunomodulatory activity
Effects on metabolism of reactive oxygen
All gold drugs rapidly bind to proteins containing thiol
side chains, but not DNA.
[Au(CN)2]- is a common metabolite of all Au drugs
Au(I) oxidised to Au(III) in vivo
ESI-MS of Human Serum Albumin (HSA)
J. Croft, CHEM340, 2004
Reaction between [Au(PEt3)Cl] and
Metallothionein
S. Ambehara, B.Sc(Hons), 20002
Covalent Binding of Ruthenium
Compounds to DNA
J. Torrens, B.Sc(Hons), 2000
Non-covalent Interactions Between
Ruthenium Complexes and DNA
2
N
N
N
N
N
N
N
N
Ru
N
N
N
N
N
N
N
[Ru(phen) 2(dpq)] 2+
2
N
N
N
N
CH3
N
N
N
N
N
N
N
Ru
Ru
N
[Ru(phen) 2(pda) ]2+
2
2
N
N
N
N
N
[Ru(phen) 3]2+
N
Ru
Ru
N
N
2
2
N
N
CH3
[Ru(phen) 2(dpqMe 2)]2+
[Ru(phen) 2(dpqC)] 2+
J. Aldrich-Wright and co-workers
N
N
N
Ru
N
N
N
N
[Ru(phen) 2(dppz)] 2+
ESI-MS of D2
[D2-6H]6-
[D2-5H]5-
T. Urathamakul, B.Sc(Hons), 2002
ESI-MS of [Ru(phen)2(dpqC)]2+
(mol. wt = 748)
T. Urathamakul, B.Sc(Hons), 2002
Reactions between [Ru(phen)3]2+ and
D2
T. Urathamakul, B.Sc(Hons), 2002
Ru:D2 = 5:1
Ru:D2 = 10:1
Ru:D2 = 20:1
Ru:D2 = 30:1
Ru:D2 = 50:1
L = phen
L = pda
L = dpq
Reactions between
[Ru(phen)2L]2+
and D2
T. Urathamakul
B.Sc(Hons), 2002
L = dpqMe2
L = dpqC
L = dppz
Future Work
Binding of mono- and
poly-nuclear ruthenium
complexes to longer DNA
and DNA containing other
base sequences
Binding of gold,
vanadium, bismuth,
ruthenium and other
metal-containing drugs to
proteins including HSA,
MT and Transferrin